GlassScriptPhysician profile
Michael Todd Emmons
NPI 1417950726
$825.42
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $107 · 2021: $125 · 2023: $32.36 · 2024: $42.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $190.21 | 2019-2020 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Lilly USA, LLC | $121.62 | 2019 | |
| Amgen INC. | $66.54 | 2019 | |
| Allergan, INC. | $47.54 | 2019 | |
| Pfizer INC. | $36.19 | 2019 | |
| Gilead Sciences, INC. | $29.35 | 2024 | Trodelvy |
| Hologic Sales and Service, LLC | $28.69 | 2023-2024 | Omni Hysteroscope, Acessa Provu System |
| Nalpropion Pharmaceuticals LLC | $23.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.42 | 2019 | |
| Novo Nordisk INC | $22.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.41 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.26 | 2019 | |
| Astellas Pharma US INC | $17.56 | 2019 | |
| Mml US, INC. | $17.16 | 2023 | Reactiv8 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.84 | 2019 | |
| Merck Sharp & Dohme LLC | $11.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Emmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.